MIP-Based Sensors: Promising New Tools for Cancer Biomarker Determination

Abstract

Detecting cancer disease at an early stage is one of the most important issues for increasing the survival rate of patients. Cancer biomarker detection helps to provide a diagnosis before the disease becomes incurable in later stages. Biomarkers can also be used to evaluate the progression of therapies and surgery treatments. In recent years, molecularly imprinted polymer (MIP) based sensors have been intensely investigated as promising analytical devices in several fields, including clinical analysis, offering desired portability, fast response, specificity, and low cost. The aim of this review is to provide readers with an overview on recent important achievements in MIP-based sensors coupled to various transducers (e.g., electrochemical, optical, and piezoelectric) for the determination of cancer biomarkers by selected publications from 2012 to 2016.

Advance detection technologies for select biothreat agents

“…Thus MIPs have been used as antibody/ receptor binding mimics in immunoassay-type analyses, as enzyme mimics catalytic applications and as recognition matrices in biosensors. Sensitive detection systems will be developed using MIPs against selected toxins (Selvolini and Giovanna, 2017).…”

Electrochemical Detection of Vascular Endothelial Growth Factor by Molecularly Imprinted Polymer

“…These artificial receptors are biomimetic structures, which mimic the sensing characteristics of the biological materials. One of these artificial receptors is known as molecularly imprinted polymer (MIP) .…”

Design of a New Peptide Substrate Probe of the Putative Biomarker Legumain with Potential Application in Prostate Cancer Diagnosis Ex Vivo

“…Early diagnosis of Pca is usually reliant on techniques that include digital rectal examination, magnetic resonance imaging and transrectal ultrasound-guided biopsy in conjunction with screening for serum levels of prostate specific antigen (PSA) which remains the principal biomarker for Pca (Zhang et al 2017). A challenge across the spectrum of cancers is to identify and incorporate into clinical practice, well-defined and validated diagnostic and predictive biomarkers of disease (Dijkstra et al 2012;Hemminki et al 2012;Selvolini and Marrazza 2017;Ueland 2017).…”